<DOC>
	<DOCNO>NCT02918929</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled study ass safety , tolerability , pharmacokinetics single multiple orally administer dose EDP-305 healthy adult subject , adult subject presumptive NAFLD ( i.e. , obese subject without prediabetes T2DM ) .</brief_summary>
	<brief_title>A Study EDP 305 Healthy Subjects Subjects With Presumptive NAFLD</brief_title>
	<detailed_description>The first phase assess single ascend dos EDP 305 ( active drug placebo ) healthy subject . A `` fasted '' `` feed '' two-part cohort also assess food effect . The second phase assess multiple ascend dos ( active drug placebo ) 14-days healthy subject also subject presumptive NAFLD ( i.e. , obese subject without prediabetes T2DM ) . Each cohort within phase enroll total 8 subject randomize receive EDP-305 placebo . The cohort assess food effect enroll 10 subject randomize receive EDP-305 placebo .</detailed_description>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<criteria>Inclusion Criteria SAD MAD Subjects : : An informed consent document sign date subject . Healthy male female subject ethnic origin age 18 55 year , inclusive . Female subject must nonchildbearing potential . All male participant vasectomy must use effective contraception Day 1 90 day last dose study drug . For healthy volunteer ( see Subjects presumptive NAFLD ) : Body mass index 18 30 kg/m2 minimum body weight 50 kg . Additional Inclusion Criteria MAD Subjects Presumptive NAFLD : Body mass index &gt; 28 &lt; 35 kg/m2 screening . WITH WITHOUT one following : Type 2 diabetes mellitus diagnose one follow method : As defined American Diabetes Association ( ADA ) , one follow criterion : ) symptom diabetes plus casual plasma glucose concentration &gt; 200 mg/dL ( 11.1 mmol/L ) OR b ) Fasting plasma glucose &gt; 126 mg/dL ( 7.0 mmol/L ) OR c ) 2hour postload glucose &gt; 200 mg/dL ( 11.1 mmol/L ) 75 g oGTT . HbA1c least 6.5 % . OR Prediabetes diagnose define ADA ) HbA1c 5.7 % 6.4 % OR b ) fast blood glucose 100125 mg/dL OR c ) oGTT 2hour blood glucose 140 mg/dL 199 mg/dL . Clinically relevant evidence history illness disease . Pregnant nursing female . History febrile illness within 7 day prior first dose study drug subject evidence active infection . A positive urine drug screen screen Day 1 . Current tobacco smoker use tobacco within 3 month prior screen . Any condition possibly affect drug absorption ( e.g. , gastrectomy , cholecystectomy ) . History regular alcohol consumption Participation clinical trial within 30 day prior study drug administration . Use prescription drug , nonprescription drug , dietary supplement include Vitamin E herbal supplement , hormonal therapy/replacement CYP3A4 substrates , inducer inhibitor within 14 day prior first dose study medication . Additional Exclusion Criteria MAD Subjects Presumptive NAFLD : Subjects take antidiabetic medication . Subjects unstable proliferative retinopathy , macular oedema ( fundus examination perform previous year consider relevant Investigator 's judgement ) . Subject take fibrates , statin , and/or Vitamin E within 6 week prior first dose administration . Subjects history bariatric surgery gastrointestinal surgery relative weight loss . Subjects common cause secondary hepatic steatosis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>First-in-human</keyword>
	<keyword>Single Ascending Dose</keyword>
	<keyword>Multiple Ascending Dose</keyword>
</DOC>